{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:47:06Z","timestamp":1794955626689,"version":"4.9.1"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved the outcomes of patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resistance to these agents are critical for devising effective treatment strategies. We used duplex sequencing, a technology that enables detection of mutations at ultra-low allelic frequencies, to identify mutations in five genes associated with drug resistance in CLL and followed their evolution in two patients who received multiple targeted therapies and ultimately developed disease progression on pirtobrutinib. In both patients we detected variants that expanded and reached significant cancer cell fractions (CCF). In patient R001, multiple known resistance mutations in both BTK and PLCG2 appeared following progression on zanubrutinib (BTK p.L528W, p.C481S; PLCG2 S707F, L845F, R665W, and D993H). In contrast, patient R002 developed multiple BTK mutations following acalabrutinib treatment, including known resistance mutations p.C481R, p.T474I and p.C481S. We found that pirtobrutinib was able to suppress, but not completely eradicate, BTK p.C481S mutations in both patients, but other resistance mutations such as mutations in PLCG2 and new BTK mutations increased while the patients were receiving pirtobrutinib. For example, BTK p.L528W in patient R001 increased in frequency more than 1,000-fold (from a CCF of 0.02% to 35%), and the CCF in p.T474I in patient R002 increased from 0.03% to 4.2% (more than 100-fold). Our data illuminate the evolutionary dynamics of resistant clones over the patients\u2019 disease course and under selective pressure from different targeted treatments.<\/jats:p>","DOI":"10.3324\/haematol.2023.283372","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T04:55:37Z","timestamp":1694667337000},"page":"835-845","source":"Crossref","is-referenced-by-count":7,"title":["Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies"],"prefix":"10.3324","volume":"109","author":[{"given":"David W.","family":"Woolston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Latorre-Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ray","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan F.","family":"Kohrn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Ana","family":"Risques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia C.S.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"58417","doi-asserted-by":"crossref","unstructured":"Wierda WG, Brown J, Abramson JS. NCCN Guidelines\u00ae Insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022; 20(6):622-634.","DOI":"10.6004\/jnccn.2022.0031"},{"key":"58418","doi-asserted-by":"crossref","unstructured":"Honigberg LA, Smith AM, Sirisawad M. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-13080.","DOI":"10.1073\/pnas.1004594107"},{"key":"58419","doi-asserted-by":"crossref","unstructured":"Yeung CCS, Shadman M. How to choose the best treatment and testing for chronic lymphocytic leukemia in the tsunami of new treatment options. Curr Oncol Rep. 2019; 21(8):74.","DOI":"10.1007\/s11912-019-0819-x"},{"key":"58420","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42.","DOI":"10.1056\/NEJMoa1215637"},{"key":"58421","doi-asserted-by":"crossref","unstructured":"Barr PM, Owen C, Robak T. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022; 6(11):3440-3450.","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"58422","doi-asserted-by":"crossref","unstructured":"Munir T, Brown JR, O\u2019Brien S. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94(12):1353-1363.","DOI":"10.1002\/ajh.25638"},{"key":"58423","doi-asserted-by":"crossref","unstructured":"Furman RR, Cheng S, Lu P. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014; 370(24):2352-2354.","DOI":"10.1056\/NEJMc1402716"},{"key":"58424","doi-asserted-by":"crossref","unstructured":"Sedlarikova L, Petrackova A, Papajik T, Turcsanyi P, Kriegova E. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020; 10:894.","DOI":"10.3389\/fonc.2020.00894"},{"key":"58425","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Guinn D. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017; 35(13):1437-1443.","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"58426","doi-asserted-by":"crossref","unstructured":"Liu T-M, Woyach JA, Zhong Y. Hypermorphic mutation of phospholipase C, g2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015; 126(1):61-68.","DOI":"10.1182\/blood-2015-02-626846"},{"key":"58427","doi-asserted-by":"crossref","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1(1):80-87.","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"58428","doi-asserted-by":"crossref","unstructured":"Woyach J, Huang Y, Rogers K. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood. 2019; 134(Suppl_1):504.","DOI":"10.1182\/blood-2019-127674"},{"key":"58429","doi-asserted-by":"crossref","unstructured":"Bonfiglio S, Sutton L-A, Ljungstr\u00f6m V. BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023; 7(12):2794-2806.","DOI":"10.1182\/bloodadvances.2022008821"},{"key":"58430","doi-asserted-by":"crossref","unstructured":"Ahn IE, Brown JR. Targeting Bruton\u2019s tyrosine kinase in CLL. Front Immunol. 2021; 12:687458.","DOI":"10.3389\/fimmu.2021.687458"},{"key":"58431","doi-asserted-by":"crossref","unstructured":"Kittai AS, Woyach JA. Resistance mechanisms to targeted agents in chronic lymphocytic leukemia. Cancer J. 2019; 25(6):428-435.","DOI":"10.1097\/PPO.0000000000000406"},{"key":"58432","doi-asserted-by":"crossref","unstructured":"Mato AR, Nabhan C, Thompson MC. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103(5):874-879.","DOI":"10.3324\/haematol.2017.182907"},{"key":"58433","doi-asserted-by":"crossref","unstructured":"Brandhuber B, Gomez E, Smith S. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk. 2018; 18(Suppl 1):S216.","DOI":"10.1016\/j.clml.2018.07.081"},{"key":"58434","doi-asserted-by":"crossref","unstructured":"Gomez EB, Isabel L, Rosendahal MS, Rothenberg SM, Andrews SW, Brandhuber BJ. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Blood. 2019; 134(Suppl_1):4644.","DOI":"10.1182\/blood-2019-126114"},{"key":"58435","doi-asserted-by":"crossref","unstructured":"Naeem AS, Nguy WI, Tyekucheva S. LOXO-305: targeting C481S Bruton tyrosine kinase in patients with ibrutinibresistant CLL. Blood. 2019; 134(Suppl_1):478.","DOI":"10.1182\/blood-2019-124362"},{"key":"58436","doi-asserted-by":"crossref","unstructured":"Mato AR, Shah NN, Jurczak W. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021; 397(10277):892-901.","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"58437","doi-asserted-by":"crossref","unstructured":"Xu Y, Ye H. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp Hematol Oncol. 2022; 11(1):31.","DOI":"10.1186\/s40164-022-00283-0"},{"key":"58438","doi-asserted-by":"crossref","unstructured":"Tariq S, Tariq S, Khan M, Azhar A, Baig M. Venetoclax in the treatment of chronic lymphocytic leukemia: evidence, expectations, and future prospects. Cureus. 2020; 12(6):e8908.","DOI":"10.7759\/cureus.8908"},{"key":"58439","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RR. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019; 37(16):1391-1402.","DOI":"10.1200\/JCO.18.01460"},{"key":"58440","doi-asserted-by":"crossref","unstructured":"Klein U. Resolving PI3K-\u03b4 inhibitor resistance in CLL. Blood. 2019; 134(6):496-498.","DOI":"10.1182\/blood.2019001177"},{"key":"58441","doi-asserted-by":"crossref","unstructured":"Iskierka-Ja\u017cd\u017cewska E, Obracaj A, Urbaniak M, Robak T. New treatment options for newly-diagnosed and relapsed chronic lymphocytic leukemia. Curr Treat Options Oncol. 2022; 23(6):775-795.","DOI":"10.1007\/s11864-022-00974-0"},{"key":"58442","doi-asserted-by":"crossref","unstructured":"Wierda WG, Rawstron A, Cymbalista F. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021; 35(11):3059-3072.","DOI":"10.1038\/s41375-021-01241-1"},{"key":"58443","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Marco JA, Jim\u00e9nez JL, Recasens V. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. Haematologica. 2019; 104(11):2249-2257.","DOI":"10.3324\/haematol.2018.204891"},{"key":"58444","doi-asserted-by":"crossref","unstructured":"Del Giudice I, Raponi S, Della Starza I. Minimal residual disease in chronic lymphocytic leukemia: a new goal?. Front Oncol. 2019; 9:689.","DOI":"10.3389\/fonc.2019.00689"},{"key":"58445","doi-asserted-by":"crossref","unstructured":"Ruppert AS, Yin J, Davidian M. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. Ann Oncol. 2019; 30(4):542-550.","DOI":"10.1093\/annonc\/mdz053"},{"key":"58446","doi-asserted-by":"crossref","unstructured":"Short NJ, Kantarjian H, Kanagal-Shamanna R. Ultra-accurate duplex sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020; 10(5):61.","DOI":"10.1038\/s41408-020-0329-y"},{"key":"58447","doi-asserted-by":"crossref","unstructured":"Kamath-Loeb AS, Shen J-C, Schmitt MW. Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation duplex sequencing. Leuk Res. 2022; 115:106822.","DOI":"10.1016\/j.leukres.2022.106822"},{"key":"58448","doi-asserted-by":"crossref","unstructured":"Schmitt MW, Pritchard JR, Leighow SM. Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias. Clin Cancer Res. 2018; 24(21):5321-5334.","DOI":"10.1158\/1078-0432.CCR-18-0167"},{"key":"58449","doi-asserted-by":"crossref","unstructured":"Kennedy SR, Schmitt MW, Fox EJ. Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc. 2014; 9(11):2586-2606.","DOI":"10.1038\/nprot.2014.170"},{"key":"58450","doi-asserted-by":"crossref","unstructured":"Krimmel JD, Schmitt MW, Harrell MI. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A. 2016; 113(21):6005-6010.","DOI":"10.1073\/pnas.1601311113"},{"key":"58451","doi-asserted-by":"crossref","unstructured":"Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012; 109(36):14508-14513.","DOI":"10.1073\/pnas.1208715109"},{"key":"58452","doi-asserted-by":"crossref","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018; 19(5):269-285.","DOI":"10.1038\/nrg.2017.117"},{"key":"58453","doi-asserted-by":"crossref","unstructured":"Malcikova J, Pavlova S, Kunt Vonkova B. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options. Blood. 2021; 138(25):2670-2685.","DOI":"10.1182\/blood.2020009530"},{"key":"58454","doi-asserted-by":"crossref","unstructured":"Quinquenel A, Fornecker L-M, Letestu R. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019; 134(7):641-644.","DOI":"10.1182\/blood.2019000854"},{"key":"58455","doi-asserted-by":"crossref","unstructured":"Burger JA, Landau DA, Taylor-Weiner A. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016; 7(1):11589.","DOI":"10.1038\/ncomms11589"},{"key":"58456","doi-asserted-by":"crossref","unstructured":"Landau DA, Sun C, Rosebrock D. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017; 8(1):2185.","DOI":"10.1038\/s41467-017-02329-y"},{"key":"58457","doi-asserted-by":"crossref","unstructured":"Mato AR, Pagel JM, Coombs CC. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: updated results from the phase 1\/2 BRUIN study. Blood. 2021; 138(Suppl 1):391-391.","DOI":"10.1182\/blood-2021-147599"},{"key":"58458","doi-asserted-by":"crossref","unstructured":"Blombery P, Thompson ER, Lew TE. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022; 6(20):5589-5592.","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"58459","doi-asserted-by":"crossref","unstructured":"Wang E, Mi X, Thompson MC. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022; 386(8):735-743.","DOI":"10.1056\/NEJMoa2114110"},{"key":"58460","doi-asserted-by":"crossref","unstructured":"Naeem A, Utro F, Wang Q. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023; 7(9):1929-1943.","DOI":"10.1182\/bloodadvances.2022008447"},{"key":"58461","doi-asserted-by":"crossref","unstructured":"Blombery P, Lew TE, Dengler MA. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022; 139(8):1198-1207.","DOI":"10.1182\/blood.2021012775"},{"key":"58462","doi-asserted-by":"crossref","unstructured":"Thomalla D, Beckmann L, Grimm C. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022; 140(20):2113-2126.","DOI":"10.1182\/blood.2021014304"},{"key":"58463","doi-asserted-by":"crossref","unstructured":"Moujalled DM, Brown FC, Pomilio G. Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia. Blood. 2020; 136(Suppl 1):7-8.","DOI":"10.1182\/blood-2020-136872"},{"key":"58464","doi-asserted-by":"crossref","unstructured":"Popovic R, Dunbar F, Lu C. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. Am J Hematol. 2022; 97(2):E47-E51.","DOI":"10.1002\/ajh.26411"},{"key":"58465","doi-asserted-by":"crossref","unstructured":"Thijssen R, Tian L, Anderson MA. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022; 140(20):2127-2141.","DOI":"10.1182\/blood.2022016040"},{"key":"58466","doi-asserted-by":"crossref","unstructured":"Blombery P, Thompson ER, Chen X. BAX-mutated clonal hematopoiesis in patients on long-term venetoclax for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2020; 136(Suppl 1):9-10.","DOI":"10.1182\/blood-2020-137775"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283372\/76050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283372\/76670","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11262\/76050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:51Z","timestamp":1794045891000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283372","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}